<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>U.S.</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Mobia debuts on Nasdaq to bring stroke therapy to more patients</title>
      <description>
        <![CDATA[Mobia Medical Inc. began trading on Nasdaq under the ticker MOBI on May 8. The company priced its IPO at the midpoint of its proposed $14 to $16 range, selling 10 million shares at $15 each and raising approximately $150 million. The stock closed at $11.75 its first day of trading, down 21.7%. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730982</guid>
      <pubDate>Fri, 08 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730982-mobia-debuts-on-nasdaq-to-bring-stroke-therapy-to-more-patients</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Mobia-Medical-Vivistim-5-8.webp?t=1778271314" type="image/jpeg" medium="image" fileSize="79665">
        <media:title type="plain">Mobia Medical Vivistim system</media:title>
        <media:description type="plain">Vivistim Paired VNS system. Credit: Mobia Medical Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Odyssey’s IPO, placement brings $304M to lead drugs in IBD, lupus</title>
      <description>
        <![CDATA[Raising $279 million in an IPO and another $25 million in a concurrent private placement, Odyssey Therapeutics Inc. is advancing its lead phase II asset, OD-001, in ulcerative colitis, with plans to bring its SLC15A4 program into the clinic for lupus.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730980</guid>
      <pubDate>Fri, 08 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730980-odysseys-ipo-placement-brings-304m-to-lead-drugs-in-ibd-lupus</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/IPO-coins.webp?t=1588705630" type="image/png" medium="image" fileSize="384858">
        <media:title type="plain">IPO, coins, financial chart</media:title>
      </media:content>
    </item>
    <item>
      <title>Budo judo moves aplenty for Climb in autoimmune</title>
      <description>
        <![CDATA[Climb Bio Inc. outlined May 5 an enticing data spill ahead this year with Fc-enhanced monoclonal antibody budoprutug (budo) in autoimmune diseases. Mizuho analyst Joseph Catanzaro appreciated in his report Wellesley Hills, Mass.-based Climb’s “conviction that CD19 represents a best-in-class pan-B-cell depletion target across antibody-mediated autoimmune diseases – a relative white space for conventional mAbs.” ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730979</guid>
      <pubDate>Fri, 08 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730979-budo-judo-moves-aplenty-for-climb-in-autoimmune</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Autoimmune-neve-cell-antibodies.webp?t=1664471508" type="image/png" medium="image" fileSize="1567007">
        <media:title type="plain">Illustration of antibodies attacking nerve cells</media:title>
      </media:content>
    </item>
    <item>
      <title>Hantavirus is ‘sentinel’ more than acute pandemic threat</title>
      <description>
        <![CDATA[News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press conference on Thursday, officials from the WHO did their best to calm the public’s fears that the <em>MV Hondius</em>, the ship currently heading to the Canary Islands with its remaining passengers plus assorted medical, WHO and European Center for Disease Prevention and Control staff, is the 2026 version of the <em>Diamond Princess</em>.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731113</guid>
      <pubDate>Fri, 08 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731113-hantavirus-is-sentinel-more-than-acute-pandemic-threat</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Cruise-ship.webp?t=1778189869" type="image/jpeg" medium="image" fileSize="257901">
        <media:title type="plain">Close up of bow of cruise ship</media:title>
      </media:content>
    </item>
    <item>
      <title>Hantavirus is ‘sentinel’ more than acute pandemic threat</title>
      <description>
        <![CDATA[News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press conference on Thursday, officials from the WHO did their best to calm the public’s fears that the <em>MV Hondius</em>, the ship currently heading to the Canary Islands with its remaining passengers plus assorted medical, WHO and European Center for Disease Prevention and Control staff, is the 2026 version of the <em>Diamond Princess</em>.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730969</guid>
      <pubDate>Fri, 08 May 2026 07:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730969-hantavirus-is-sentinel-more-than-acute-pandemic-threat</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Cruise-ship.webp?t=1778189869" type="image/jpeg" medium="image" fileSize="257901">
        <media:title type="plain">Close up of bow of cruise ship</media:title>
      </media:content>
    </item>
    <item>
      <title>Atara rises on new FDA pathway for Ebvallo resubmission </title>
      <description>
        <![CDATA[Atara Biotherapeutics Inc.’s allogeneic T-cell immunotherapy, Ebvallo (tabelecleucel), for Epstein-Barr virus-positive post-transplant lymphoproliferative disease isn’t out of the running yet. Despite grim predictions in the wake of the U.S. FDA’s second complete response letter for the drug in January, Atara and partner Pierre Fabre Pharmaceuticals Inc. reached agreement with the regulator on a path for resubmitting the BLA.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730972</guid>
      <pubDate>Thu, 07 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730972-atara-rises-on-new-fda-pathway-for-ebvallo-resubmission</link>
    </item>
    <item>
      <title>FDA slowdown on Tzield sBLA underlines CNPV questions</title>
      <description>
        <![CDATA[Reports that Sanofi SA has asked to withdraw its sBLA for Tzield (teplizumab) from the U.S. FDA’s Commissioner’s National Priority Voucher (CNPV) program is once again raising questions about whether leadership skepticism is overruling approval decisions at the agency.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730970</guid>
      <pubDate>Thu, 07 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730970-fda-slowdown-on-tzield-sbla-underlines-cnpv-questions</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/FDA-logo-on-textured-paper.webp?t=1762380665" type="image/jpeg" medium="image" fileSize="885470">
        <media:title type="plain">FDA logo on textured paper</media:title>
        <media:description type="plain">Credit: Araki Illustrations - stock.adobe.com</media:description>
      </media:content>
    </item>
    <item>
      <title>Phase II Engene trouble: NMIBC detalimogene data throttle stock </title>
      <description>
        <![CDATA[Hopes piqued last November for detalimogene voraplasmid in bladder cancer took a hit from the latest word from the study, as did shares of Engene Therapeutics Inc. (NASDAQ:ENGN), which closed May 7 at $1.72, down 80.6%, or $7.13.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730968</guid>
      <pubDate>Thu, 07 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730968-phase-ii-engene-trouble-nmibc-detalimogene-data-throttle-stock</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Urology/Bladder-illustration.webp?t=1615559821" type="image/png" medium="image" fileSize="432209">
        <media:title type="plain">Bladder </media:title>
      </media:content>
    </item>
    <item>
      <title>Entrada sinks on mixed DMD data with ENTR-601-44</title>
      <description>
        <![CDATA[A lower-than-expected increase in dystrophin over baseline in the first and lowest-dose cohort of a phase I/II study of ENTR-601-44 in Duchenne muscular dystrophy (DMD) caused shares of Entrada Therapeutics Inc. to plunge more than 57%, despite the cohort meeting the safety and tolerability primary objective.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730967</guid>
      <pubDate>Thu, 07 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730967-entrada-sinks-on-mixed-dmd-data-with-entr-601-44</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Red-arrow-pointing-downward-on-a-stock-market-ticker.webp?t=1746653867" type="image/jpeg" medium="image" fileSize="239034">
        <media:title type="plain">Red arrow pointing downward on a stock market ticker</media:title>
      </media:content>
    </item>
    <item>
      <title>Roche to acquire Pathai for up to $1.05B</title>
      <description>
        <![CDATA[Roche Holding AG has agreed to acquire Pathai Inc. for up to $1.05 billion in a bid to strengthen its position in digital pathology and enhance its biopharma services. The move builds on a partnership established between the two companies in 2021, and expanded in 2024, to include the development of AI-enabled companion diagnostic algorithms.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730966</guid>
      <pubDate>Thu, 07 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730966-roche-to-acquire-pathai-for-up-to-105b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Roche-building.webp?t=1698088417" type="image/jpeg" medium="image" fileSize="310241">
        <media:title type="plain">Roche building</media:title>
        <media:description type="plain">Credit: F. Hoffmann-La Roche Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst</title>
      <description>
        <![CDATA[Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash deal worth $4.1 billion. The acquisition gives Angelini ownership of three marketed drugs for treating epilepsy and neuromuscular diseases that had combined sales of $589 million in 2025, a 19.8% increase over 2024.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730965</guid>
      <pubDate>Thu, 07 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730965-italys-angelini-pays-41b-cash-for-rare-disease-specialist-catalyst</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Neuro-illustration.webp?t=1628534498" type="image/png" medium="image" fileSize="616001">
        <media:title type="plain">Neurology illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>US FDA tries out 1-day inspections</title>
      <description>
        <![CDATA[Even before the U.S. FDA announced its one-day inspection pilot May 6, it already had test-flown 46 of the shorter inspections across several of its centers.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730852</guid>
      <pubDate>Thu, 07 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730852-us-fda-tries-out-1-day-inspections</link>
    </item>
    <item>
      <title>Multiple appearances on Priority Watch List leading to action?</title>
      <description>
        <![CDATA[It’s a sure bet when the U.S. Trade Representative releases its annual Special 301 Report that Chile, China, India, Indonesia, Russia and Venezuela will be on the Priority Watch List. The 2026 report was no exception.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730867</guid>
      <pubDate>Wed, 06 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730867-multiple-appearances-on-priority-watch-list-leading-to-action</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Magnifying-glass-on-wooden-table.webp?t=1721409551" type="image/jpeg" medium="image" fileSize="152426">
        <media:title type="plain">Magnifying glass on wooden table</media:title>
      </media:content>
    </item>
    <item>
      <title>Resmed boosts sleep health portfolio with Noctrix buy</title>
      <description>
        <![CDATA[Resmed Corp. has agreed to acquire Noctrix Health Inc. for $340 million, boosting its sleep health portfolio. Noctrix has developed Nidra, a wearable neuromodulation device which treats restless legs syndrome (RLS) without disrupting sleep. With RLS impacting approximately 7% of adults globally, including about 17 million people in the U.S., the technology offers a non-drug option that could potentially treat a significant proportion of this patient population.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730863</guid>
      <pubDate>Wed, 06 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730863-resmed-boosts-sleep-health-portfolio-with-noctrix-buy</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Noctrix-Health-Nidra-system-5-6.webp?t=1778095493" type="image/jpeg" medium="image" fileSize="97350">
        <media:title type="plain">Noctrix Health Nidra system</media:title>
        <media:description type="plain">Nidra, a wearable neuromodulation device for restless legs syndrome. Credit: Noctrix Health Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Bayer buying Perfuse for $300M up front in potential $2.45B deal </title>
      <description>
        <![CDATA[In its first substantial M&A transaction since 2021, Bayer AG is buying Perfuse Therapeutics Inc., a firm that has operated quietly, though it reported positive midstage data last year for PER-001, an endothelin antagonist, in glaucoma and diabetic retinopathy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730862</guid>
      <pubDate>Wed, 06 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730862-bayer-buying-perfuse-for-300m-up-front-in-potential-245b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-and-financial-charts.webp?t=1685051887" type="image/jpeg" medium="image" fileSize="207505">
        <media:title type="plain">Eye and financial charts</media:title>
      </media:content>
    </item>
    <item>
      <title>Bio Korea 2026 kicks off with spotlight on oligonucleotides</title>
      <description>
        <![CDATA[Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and the promise of “programmable,” precision medicine for patients, speakers at Bio Korea 2026 said April 28.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730927</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730927-bio-korea-2026-kicks-off-with-spotlight-on-oligonucleotides</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Researcher-antisense-oligonucleotides.webp?t=1775662140" type="image/jpeg" medium="image" fileSize="579461">
        <media:title type="plain">AI generated image for researcher developing antisense oligonucleotides</media:title>
      </media:content>
    </item>
    <item>
      <title>Bio Korea 2026: US policy risks shift to execution framework</title>
      <description>
        <![CDATA[Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies can tailor regulatory strategies early, and across the entire development cycle.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730926</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730926-bio-korea-2026-us-policy-risks-shift-to-execution-framework</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Strategy-compass.webp?t=1777923242" type="image/jpeg" medium="image" fileSize="113016">
        <media:title type="plain">Strategy compass</media:title>
      </media:content>
    </item>
    <item>
      <title>Beone eyes Huahui Health’s trispecific HH-160 with $2B option deal</title>
      <description>
        <![CDATA[Beone Medicines Ltd. gained an exclusive option to develop cancer immunotherapy HH-160 worldwide in a deal potentially worth more than $2 billion for Huahui Health Ltd., the developer of the trispecific antibody.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730925</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730925-beone-eyes-huahui-healths-trispecific-hh-160-with-2b-option-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Antibodies.webp?t=1588025814" type="image/png" medium="image" fileSize="452955">
        <media:title type="plain">Antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>Sonire starts US study of cancer HIFU after $18M series A </title>
      <description>
        <![CDATA[Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed to ablate pancreatic tumors, after closing an $18 million series A financing round April 15.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730922</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730922-sonire-starts-us-study-of-cancer-hifu-after-18m-series-a</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Endocrine/Pancreas1.webp?t=1712602217" type="image/jpeg" medium="image" fileSize="143528">
        <media:title type="plain">Pancreas</media:title>
      </media:content>
    </item>
    <item>
      <title>How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III</title>
      <description>
        <![CDATA[Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc., of Hong Kong, and undergoing phase III testing in first-line squamous non-small-cell lung cancer (NSCLC).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730921</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730921-how-to-summit-up-dis-harmoni-on-ivonescimab-nsclc-phase-iii</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Lung-cancer-xray.webp?t=1663711137" type="image/png" medium="image" fileSize="257656">
        <media:title type="plain">Xray showing lung cancer on tablet</media:title>
      </media:content>
    </item>
    <item>
      <title>USTR calls out trade partners for Rx, med-tech pricing policies </title>
      <description>
        <![CDATA[For the first time in 13 years, the U.S. Trade Representative (USTR) singled out one of the U.S. trading partners as the worst of the worst when it named Vietnam as a Priority Foreign Country (PFC) in its newly released Special 301 Report.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730920</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730920-ustr-calls-out-trade-partners-for-rx-med-tech-pricing-policies</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/Map-of-Vietnam.webp?t=1777928544" type="image/jpeg" medium="image" fileSize="172581">
        <media:title type="plain">Map of Vietnam</media:title>
      </media:content>
    </item>
    <item>
      <title>Madrigal expands MASH pipeline in potential $1B Arrowhead deal</title>
      <description>
        <![CDATA[Three years after Johnson & Johnson handed back rights to an siRNA candidate targeting a genetic driver of metabolic dysfunction-associated steatohepatitis (MASH), Arrowhead Pharmaceuticals Inc. found a new partner in Madrigal Pharmaceuticals Inc., a firm that markets the first U.S. FDA-approved MASH drug, Rezdiffra (resmetirom), and has been building a pipeline in the space.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730851</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730851-madrigal-expands-mash-pipeline-in-potential-1b-arrowhead-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-and-DNA.webp?t=1602177503" type="image/png" medium="image" fileSize="311397">
        <media:title type="plain">Liver and DNA</media:title>
      </media:content>
    </item>
    <item>
      <title>White House looks to expand MFN pricing for $530B-plus in savings </title>
      <description>
        <![CDATA[Amid calls for transparency on the most-favored nation (MFN) pricing deals U.S. President Donald Trump has reached with 17 biopharma companies, the White House Council of Economic Advisers released a report May 5 detailing how the volunteer MFN policy works and touting the $530 billion-plus in savings it’s projected to deliver over the next 10 years.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730850</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730850-white-house-looks-to-expand-mfn-pricing-for-530b-plus-in-savings</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Drug-pricing-illustration.webp?t=1598557470" type="image/png" medium="image" fileSize="365578">
        <media:title type="plain">Prescription drug bottle, pills shaped in $ sign</media:title>
      </media:content>
    </item>
    <item>
      <title>MMI’s Symani system treats Alzheimer’s patient in IDE study</title>
      <description>
        <![CDATA[Medical Microinstruments Inc.’s (MMI) Symani surgical system was used to treat a patient with Alzheimer’s disease as part of a study evaluating robotic-enabled microsurgery for the condition. The procedure investigated whether restoring lymphatic drainage pathways in the deep cervical lymph nodes could improve the clearance of harmful neurotoxins believed to contribute to the progression of Alzheimer’s.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730849</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730849-mmis-symani-system-treats-alzheimers-patient-in-ide-study</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Symani-system-5-5.webp?t=1778015387" type="image/jpeg" medium="image" fileSize="58857">
        <media:title type="plain">Symani system</media:title>
        <media:description type="plain">Symani surgical system. Credit: Medical Microinstruments Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Cytokinetics metrics satisfy in nHCM phase III</title>
      <description>
        <![CDATA[Thanks to a trial design that, according to Evercore ISI analyst Cory Kasimov, “played out exactly as drawn up,” Cytokinetics Inc. hit both of the phase III co-primary endpoints with aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730848</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730848-cytokinetics-metrics-satisfy-in-nhcm-phase-iii</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/cardio-heart-attack.webp?t=1595367448" type="image/png" medium="image" fileSize="363148">
        <media:title type="plain">Heart illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Viridian’s Reveal-2 beats expectations with elegrobart in TED </title>
      <description>
        <![CDATA[Top-line data from the Reveal-2 phase III trial of elegrobart to treat chronic thyroid eye disease (TED) drove Viridian Therapeutics Inc.’s stock up by 33.6%, positioning the company for a BLA filing in the first quarter of 2027. The trial met both primary endpoints at week 24: proptosis responder rate, as measured by exophthalmometry, required for a filing with the U.S. FDA; and the overall responder rate, required for an EMA filing. Doses every four weeks or every eight weeks achieved 50% and 54% PRR, respectively, compared to 15% for placebo. The doses also achieved 47% and 54% ORR vs. 15% for placebo. ORR included those with both proptosis and Clinical Activity Score response, defined as no worsening from baseline in the study eye, without deterioration in the fellow eye.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730847</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730847-viridians-reveal-2-beats-expectations-with-elegrobart-in-ted</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-with-digital-overlay.webp?t=1717017591" type="image/jpeg" medium="image" fileSize="355984">
        <media:title type="plain">Eye with digital overlay</media:title>
      </media:content>
    </item>
    <item>
      <title>Bio Korea 2026: US policy risks shift to execution framework</title>
      <description>
        <![CDATA[Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies can tailor regulatory strategies early, and across the entire development cycle.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730835</guid>
      <pubDate>Mon, 04 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730835-bio-korea-2026-us-policy-risks-shift-to-execution-framework</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Strategy-compass.webp?t=1777923242" type="image/jpeg" medium="image" fileSize="113016">
        <media:title type="plain">Strategy compass</media:title>
      </media:content>
    </item>
    <item>
      <title>Celcuity rises on gedatolisib on top-line data in breast cancer </title>
      <description>
        <![CDATA[As Celcuity Inc. awaits a U.S. FDA approval decision for gedatolisib in HER-positive, HER2-negative, PIK3CA wild-type advanced breast cancer, the company already is setting its sights on a supplemental NDA filing, based on a top-line readout of the multi-target PAM inhibitor in a PIK3CA-mutant breast cancer cohort.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730833</guid>
      <pubDate>Mon, 04 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730833-celcuity-rises-on-gedatolisib-on-top-line-data-in-breast-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Breast-cancer-illustration.webp?t=1755012743" type="image/jpeg" medium="image" fileSize="458149">
        <media:title type="plain">Breast cancer illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>USTR calls out trade partners for Rx, med-tech pricing policies </title>
      <description>
        <![CDATA[For the first time in 13 years, the U.S. Trade Representative (USTR) singled out one of the U.S. trading partners as the worst of the worst when it named Vietnam as a Priority Foreign Country (PFC) in its newly released Special 301 Report.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730832</guid>
      <pubDate>Mon, 04 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730832-ustr-calls-out-trade-partners-for-rx-med-tech-pricing-policies</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/Map-of-Vietnam.webp?t=1777928544" type="image/jpeg" medium="image" fileSize="172581">
        <media:title type="plain">Map of Vietnam</media:title>
      </media:content>
    </item>
    <item>
      <title>Up to BAT in PSC, Mirum base case proven with phase IIb</title>
      <description>
        <![CDATA[Entering what Mirum Pharmaceuticals Inc. CEO Chris Peetz called “a new phase of growth and value creation,” the company plans to submit an NDA to the U.S. FDA in the second half of this year, based on phase IIb data from the Vistas trial with oral ileal bile acid transporter (IBAT) inhibitor volixibat in primary sclerosing cholangitis (PSC).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730831</guid>
      <pubDate>Mon, 04 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730831-up-to-bat-in-psc-mirum-base-case-proven-with-phase-iib</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/NASH-liver-disease.webp?t=1745258690" type="image/jpeg" medium="image" fileSize="287464">
        <media:title type="plain">Liver disease</media:title>
      </media:content>
    </item>
  </channel>
</rss>
